0001001316
false
0001001316
2019-10-28
2019-10-28
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
_____________
FORM
8-K
_____________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report
(Date of earliest event reported): October 28, 2019
TG
Therapeutics, Inc.
(Exact Name of
Registrant as Specified in Charter)
Delaware
(State or Other
Jurisdiction
of
Incorporation)
|
001-32639
(Commission File Number)
|
36-3898269
(IRS Employer
Identification No.)
|
2
Gansevoort Street, 9th Floor
New
York, New York 10014
(Address of
Principal Executive Offices)
(212)
554-4484
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act.
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act.
☐
Pre-commencement communications pursuant to Rule 14d-2b under the
Exchange Act.
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act.
Title of
Class
|
Trading
Symbol(s)
|
Exchange
Name
|
Common Stock, par value
$0.001
|
TGTX
|
Nasdaq Capital
Market
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2). Emerging growth company
☐
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events.
On October 28,
2019, TG Therapeutics, Inc. (the “Company”) issued a
press release announcing data from the UNITY-NHL Phase 2b pivotal
trial evaluating umbralisib in patients with relapsed/refractory
follicular lymphoma. A copy of the press release is being filed as
Exhibit 99.1 and incorporated in this Item by
reference.
Item
9.01. Financial Statements And Exhibits.
(d)
Exhibits.
99.1
Press release issued by TG Therapeutics,
Inc., dated October 28, 2019.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TG Therapeutics, Inc.
(Registrant)
By: /s/ Sean A. Power
Sean A. Power
Chief Financial Officer
Date: October
28, 2019
- 3
-